A study found that a combination of remdesivir plus dexamethasone significantly reduced the risk of death among COVID-19 patients requiring baseline oxygen compared to dexamethasone alone. The combination therapy also reduced the need for supplemental oxygen and mortality risk. However, an expert questioned why nearly half of the patients in the study were on dexamethasone despite not needing oxygen, as corticosteroids may increase mortality in these patients. The study authors recommend the use of remdesivir in combination with dexamethasone for COVID-19 patients requiring hospitalization and supplemental oxygen.
Source link
Remdesivir plus dexamethasone reduces death in COVID-19 hospitalizations
